Explore evidence

11 %Clade G accounted for 11% of the studied HIV infections in Cameroonian blood donors.

CamerounVIH/sidapublished 2013Virology JournalOpenAlexdocument of 7 observationsDOI 10.1186/1743-422x-10-29

60 %Sixty percent of the 142 strains had one mutation in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

1,070 SFU/10^6 PBMCThe median T cell response to Nef was 1070 spot forming units per 10^6 PBMC.

CamerounVIH/sidapublished 2009RetrovirologyOpenAlexdocument of 6 observationsDOI 10.1186/1742-4690-6-s3-p273

5.3 %Among ART initiators with no prior exposure to antiretrovirals in rural areas of Cameroon, pretreatment HIV drug resistance (PDR) prevalence was 5.3% (95% CI 1.4%–17.5%).

CamerounVIH/sidaobserved 2015published 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 12 observationsDOI 10.1093/jac/dky221

106 cells_per_mm3CD4 count increased by a median of 106 cells/mm3 at 12 months.

CamerounVIH/sidaobserved 12 monthspublished 2005Antiviral TherapyOpenAlexdocument of 8 observationsDOI 10.1177/135965350501000208

7.4 %HIV seroprevalence in a general population of southern Cameroon is 7.4%.

CamerounVIH/sidapublished 2007Emerging infectious diseasesOpenAlexdocument of 7 observationsDOI 10.3201/eid1303.061069

1 specimensPhylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 1 was subtype H.

CamerounVIH/sidapublished 2000AIDS Research and Human RetrovirusesOpenAlexdocument of 7 observations

9 %Nine percent of HIV sequences (29/321) were from participants reporting previous exposure to antiretrovirals.

CamerounVIH/sidaobserved 2015published 2018The Journal of antimicrobial chemotherapyeurope_pmcdocument of 12 observationsDOI 10.1093/jac/dky221

50 %Circulating recombinant form CRF02_AG accounted for 50% of the studied HIV infections in Cameroonian blood donors.

CamerounVIH/sidapublished 2013Virology JournalOpenAlexdocument of 7 observationsDOI 10.1186/1743-422x-10-29

98 %The prevalence of the 89M/I substitution in protease sequences was 98% (56/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

13.5 %Among ART initiators with no prior exposure to antiretrovirals in urban areas of Cameroon, pretreatment HIV drug resistance (PDR) prevalence was 13.5% (95% CI 5.1%–31.5%).

CamerounVIH/sidaobserved 2015published 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 12 observationsDOI 10.1093/jac/dky221

3.3 %The overall early vertical transmission rate of HIV among 1827 tested infants was 3.3% (95% CI 2.5–4.3).

CamerounVIH/sidaobserved November 2007 to October 2010published 2019Paediatrics and international child healthPubMeddocument of 7 observations

98.7 %371 out of 376 patients (98.7%) started on a first-line antiretroviral regimen that included 3TC + d4T/AZT + NVP/EFV in Cameroon.

CamerounVIH/sidapublished 2013Journal of the International AIDS Societyeurope_pmcdocument of 4 observations

4.43 aORVirologic failure was associated with the nevirapine concentration with an adjusted odds ratio of 4.43.

CamerounVIH/sidapublished 2008Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 11 observationsDOI 10.1097/qai.0b013e3181743955

89 %The prevalence of the 20I/R substitution in protease sequences was 89% (51/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

45 %In 2010, 45% of 38 ART sites in Cameroon attained the target for ARV drug supply continuity (target = 100%).

CamerounVIH/sidaobserved 2010published 2012PLoS ONEOpenAlexdocument of 5 observationsDOI 10.1371/journal.pone.0036777

7.8 %179 adults (7.8%) tested HIV-positive in the campaign.

CamerounVIH/sidaobserved 2011published 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

7.4 %The overall HIV seroprevalence rate in the study population was 7.4% (95% CI 5.2%–10.1%).

CamerounVIH/sidaobserved 2001published 2007Emerging infectious diseasesOpenAlexdocument of 7 observationsDOI 10.3201/eid1303.061069

1,776 adolescentsBetween 2004 and 2010, 1,776 adolescents commenced antiretroviral therapy (ART) at Mpilo OI ART clinic, Bulawayo.

CamerounVIH/sidaobserved 2004 to 2010published 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

20.5 %Among 458 patients who initiated antiretroviral therapy in rural district hospitals in Cameroon between 2006 and 2008, 94 (20.5%) classified at WHO clinical stage 3 had a CD4 count above 350 cells/mm³.

CamerounVIH/sidaobserved 2006-2008published 2010Tropical medicine & international health : TM & IHeurope_pmcdocument of 7 observations

0.7 %The M46I mutation was identified in 0.7% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

5 %The prevalence of the 62V substitution in protease sequences was 5% (3/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

86.9 %86.9% of the intention-to-treat population had viral load <400 copies/ml at 12 months.

CamerounVIH/sidaobserved 12 monthspublished 2005Antiviral TherapyOpenAlexdocument of 8 observationsDOI 10.1177/135965350501000208

9,360 adultsBetween 2004 and 2010, 9,360 adults commenced antiretroviral therapy (ART) at Mpilo OI ART clinic, Bulawayo.

CamerounVIH/sidaobserved 2004 to 2010published 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

The prevalence of hypercholesterolaemia was significantly increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations